-
Gan & Lee Pharmaceuticals Doses First Patient in GZR101 Phase I Study
•
China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced that the first patient has been dosed in a China-based Phase I clinical study for its drug candidate GZR101. The first-in-human study aims to evaluate the safety, tolerability, pharmacodynamics, and pharmacokinetics of the GZR101 injection and its component GZR33. Drug Details and…
-
Fosun Pharma’s FS-1502 Gets NMPA Approval for Gastric Cancer Study
•
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a Phase II clinical study for its HER2 monoclonal antibody (mAb) injection FS-1502 in HER2-expressing advanced gastric cancer patients. The study will evaluate the…
-
GeneScience’s Somatropin Wins NMPA Approval for Prader-Willi Syndrome
•
China-based Changchun GeneScience Pharmaceutical Co., Ltd announced that it has received another indication approval from the National Medical Products Administration (NMPA) for its somatropin to treat Prader-Willi Syndrome (PWS). This latest approval marks the tenth indication for the company’s somatropin and represents the first approval for a home-grown growth hormone…
-
Inmagene and HutchMed Dose First Patient in IMG-007 Global Phase I Study
•
China-based Inmagene Biopharmaceuticals and HutchMed (NASDAQ: HCM, HKG: 0013) announced the completion of first patient dosing in a global Phase I clinical study for their IMG-007 in Australia. The drug, an antagonistic monoclonal antibody (mAb) targeting OX40, was discovered by HutchMed. Inmagene owns exclusive global option rights to the drug…
-
ClinChoice Raises USD 150M in Funding Led by Legend Capital for Expansion
•
Sino-US full-service Contract Research Organization (CRO) ClinChoice has reportedly raised USD 150 million in a financing round led by Legend Capital. Other investors included Taikang Life Insurance, Sherpa Healthcare Partners, Lilly Asia Ventures, Apricot Capital, and SIP Oriza Seed Fund. The proceeds will be used for business expansion, new business…
-
InnoCare Pharma’s BCL2 Inhibitor ICP-248 Accepted for NMPA Review
•
China’s Beijing InnoCare Pharma (HKG: 9969) announced that an investigational new drug (IND) filing for its in-house developed BCL2 inhibitor ICP-248 has been accepted for review by the National Medical Products Administration (NMPA). ICP-248 is a Category 1 innovative drug with independently held intellectual property rights. Drug ProfileInnoCare plans to…
-
Shenzhen TargetRx Raises Hundreds of Millions in Series B Financing for Drug Development
•
China-based Shenzhen TargetRx, Inc., a developer of small-molecule kinase inhibitors, reportedly raised “hundreds of millions” of renminbi in a Series B financing round, with investors undisclosed. The proceeds will go towards pivotal clinical studies for TGRX-678 and TGRX-326, development of other drug candidates, and product pipeline expansion. Company and ProductsFounded…
-
Ascletis Pharma Files IND Application for ASC10 with US FDA
•
China-based Ascletis Pharma Inc. (HKG: 1672) announced that it has filed an Investigational New Drug (IND) application for ASC10, an oral RNA-dependent RNA polymerase (RdRp) inhibitor being developed to treat COVID-19, with the US FDA following a pre-IND consultation. Drug ProfileASC10 is an orally bioavailable, double prodrug of the antiviral…
